OrthoSera Medical is a clinical-stage regenerative medicine company, which utilizes the power of blood serum as a therapeutic tool.
OrthoSera’s core technology is a proprietary human serum formulation that is translated to products regulated as tissues, devices or blood derivatives. The company currently focuses on bone grafting, osteoarthritis and wound healing in dental and orthopedic indications.
Blood serum is physiological growth factor-rich biologic that has a powerful regenerative capacity. Orthosera’s propritetary serum fraction (hyperacute serum or hypACT™) is even more specific as it retains all regenerative capacities while minimizing the pro-inflammatory components.
Extensive research shows that hyperacute serum outperforms all other blood derivatives such as PRP varieties in promoting cell proliferation without affecting lineage.
BoneAlbumin™ is essentially a serum albumin-enhanced bone graft that has been shown to activate bone marrow stem cells, resulting in faster and better bone healing. This tissue product is now available and clinical studies are proving its effectiveness in sports surgery and dental treatments.
Hyperacute serum or hypACT™ is a patented technology that has shown an outstanding effect in promoting osteoarthritic bone, cartilage and mesenchymal cell proliferation. It is currently under clinical evaluation as an autologous treatment for knee osteoarthritis. Development is underway to replace the autologous blood product with an allogeneic, off-the-shelf serum with unparalleled efficacy and clinical utility. Understanding the complex nature of degenerative joint diseases OrthoSera develops companion diagnostic tools to optimize patient selection for serum therapies.
OrthoSera was actively involved in the fight against the COVID19 pandemic by offering its expertise and technical capacity during the coronavirus outbreak in Hungary. OrthoSera pioneered the convalescent plasma treatment against SARS2-CoV.
Plasma donation in Budapest
Plasma donation at the University of Physical Education. Thirty volunteers, donors came forward and offered to help. https://www.youtube.com/watch?v=P2WQHbdRDGo
Albumin Bone Graft Patent Granted in the US – Important milestone in Lacerta’s IP strategy
Krems an der Donau, Austria, 4 September 2013 – The United States Patent Office has granted the patent entitled “Method for producing...
Lacerta announces positive results of double-blind controlled study on BoneAlbumin
At the International Conference ‘Unified Scientific Approaches towards Regenerative Orthopaedics and Dentistry’ in Venice, Italy, Dr. Lacza has announced the preliminary...
Lacerta Technologies is now OrthoSera
Krems an der Donau, Austria, 26 November 2015 – Lacerta Technologies, an orthobiologics company developing serum-based solutions for musculoskeletal indications has...
OrthoSera successfully closes financing round
Krems an der Donau, Austria, 4 December 2015 – Shortly after market launch of our first product BoneAlbumin via our...